Alteogen is maintaining a slightly higher trend, firmly holding the 360,000 won level during the trading session. This comes as investment sentiment has spread across the domestic biotech sector, driven by the rally in artificial intelligence (AI) technology stocks on the US New York Stock Exchange.

As of the morning session on the 1st, Alteogen is trading at 361,500 won, up 500 won (0.14%) from the previous trading day. In early trading, the stock expanded its gains to as high as 366,000 won, and although some profit-taking sell-offs emerged afterward, it is stably defending the 360,000 won level. Trading volume remains active at over 530,000 shares, and with buying and selling tightly balanced, investor interest shows no signs of waning.

Overnight in the New York Stock Exchange, major AI-related technology stocks led the index gains. The Nasdaq Composite rose more than 1%, while the S&P 500 and the Dow Jones Industrial Average also showed strength. As risk appetite expanded, positive effects are spreading to domestic growth and biotech stocks.

The market analyzes that the biotech sector is being revisited amid a trend of global liquidity inflows centered on growth stocks. With interest rate cut expectations improving investment sentiment toward R&D-focused companies, buying momentum is flowing into representative biotech stocks. In particular, as technology exports, new drug development, and expanded collaboration with global pharmaceutical companies are cited as key investment points for the domestic biotech sector, mid- to long-term growth expectations continue, centered on large-cap stocks. The recent rebound in the US biotech index is also serving as a factor supporting the improvement in investment sentiment.

Securities firms believe that as AI and biotech establish themselves as key growth themes in global stock markets this year, interest in related sectors will persist. However, they advise that in the short term, investors should also watch for the possibility of expanded volatility depending on the direction of US Federal Reserve monetary policy, global investment sentiment, and changes in foreign investor supply and demand.

The market expects that if the strength in US stock markets continues, a favorable investment environment will be maintained for Alteogen, a leading domestic biotech stock.

[This article was written with the assistance of AI. This article is not a solicitation for investment, and the final decision and responsibility for investing lie with the investor.]